Implantica publishes Year-end Report, January - December 2024 (Q4)

Significant events in the fourth quarter Significant events in the fourth quarter Significant events after the end of the period Fourth quarter financial summary Full year financial summary Telephone conference Implantica will hold a teleconference on14 February 2025at 15:00 (CET) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast:...

Significant events in the fourth quarter

Significant events after the end of the period

Fourth quarter financial summary

Full year financial summary

Telephone conference

Implantica will hold a teleconference on 14 February 2025 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:

Webcast:
https://implantica.events.inderes.com/q4-report-2024 

Dial-in:
numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference

https://conference.inderes.com/teleconference/?id=5001390 

For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
[email protected] 

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, [email protected]

This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-14 08:00 CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-publishes-year-end-report--january---december-2024--q4-,c4105766

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/implantica-publishes-year-end-report-january--december-2024-q4-302376911.html